http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 09:02:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Humacyte+%28HUMA%29+PT+Raised+to+%242+at+Benchmark/26578604.html (Updated - June 1, 2026 9:02 AM EDT) <p>Benchmark analyst Bruce D. Jackson raised the price target on Humacyte (NASDAQ: HUMA) to $2.00 (from $1.00) while maintaining a Speculative Buy rating.</p><p>The analyst commented, "Gaining sales traction for Symvess in the vascular trauma market has been challenging, but we are encouraged by the prospects of the dialysis arteriovascular (AV) access indication launching in 2027. In Trauma, a retooled marketing effort and the recently announced VA contract could help in the U.S. market, and we anticipate that a $1.4 million order from the Kingdom of Saudi Arabia could be completed later this year http://www.streetinsider.com/Analyst+PT+Change/Humacyte+%28HUMA%29+PT+Raised+to+%242+at+Benchmark/26578604.html Mon, 01 Jun 2026 09:02:35 -0400 HUMA http://www.streetinsider.com/Analyst+Comments/Humacyte+%28HUMA%29+PT+Raised+to+%242+at+Benchmark/26578604.html (Updated - June 1, 2026 9:02 AM EDT) <p>Benchmark analyst Bruce D. Jackson raised the price target on Humacyte (NASDAQ: HUMA) to $2.00 (from $1.00) while maintaining a Speculative Buy rating.</p><p>The analyst commented, "Gaining sales traction for Symvess in the vascular trauma market has been challenging, but we are encouraged by the prospects of the dialysis arteriovascular (AV) access indication launching in 2027. In Trauma, a retooled marketing effort and the recently announced VA contract could help in the U.S. market, and we anticipate that a $1.4 million order from the Kingdom of Saudi Arabia could be completed later this year http://www.streetinsider.com/Analyst+Comments/Humacyte+%28HUMA%29+PT+Raised+to+%242+at+Benchmark/26578604.html Mon, 01 Jun 2026 09:02:35 -0400 HUMA http://www.streetinsider.com/Corporate+News/Humacyte+presents+research+on+dialysis+access+vessel+self-repair+at+VASA+meeting/26546290.html <p>Humacyte Inc. (NASDAQ: HUMA) presented research at the Vascular Access Society of the Americas 2026 symposium showing evidence of self-repair in its acellular tissue engineered vessel following repeated needle punctures for dialysis access.</p><p>The research examined explanted ATEV and ePTFE samples that had been used for dialysis access for up to 5.5 years. Dialysis patients typically undergo more than 300 needle punctures annually for treatment access.</p><p>According to the study, ATEVs maintained structural integrity despite repeated cannulations over the 5.5-year period. The vessels showed smooth muscle cell repopulation at cannulation sites and functional tissue remodeling, including capillary ingrowth and organized collagen deposition. http://www.streetinsider.com/Corporate+News/Humacyte+presents+research+on+dialysis+access+vessel+self-repair+at+VASA+meeting/26546290.html Tue, 26 May 2026 08:03:33 -0400 HUMA http://www.streetinsider.com/FDA/Humacyte+presents+research+on+dialysis+access+vessel+self-repair+at+VASA+meeting/26546290.html <p>Humacyte Inc. (NASDAQ: HUMA) presented research at the Vascular Access Society of the Americas 2026 symposium showing evidence of self-repair in its acellular tissue engineered vessel following repeated needle punctures for dialysis access.</p><p>The research examined explanted ATEV and ePTFE samples that had been used for dialysis access for up to 5.5 years. Dialysis patients typically undergo more than 300 needle punctures annually for treatment access.</p><p>According to the study, ATEVs maintained structural integrity despite repeated cannulations over the 5.5-year period. The vessels showed smooth muscle cell repopulation at cannulation sites and functional tissue remodeling, including capillary ingrowth and organized collagen deposition. http://www.streetinsider.com/FDA/Humacyte+presents+research+on+dialysis+access+vessel+self-repair+at+VASA+meeting/26546290.html Tue, 26 May 2026 08:03:33 -0400 HUMA http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Press+Releases/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html <p align="center"><em>- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - </em></p> <p align="center"><em>- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - </em></p> <p align="center"><em>- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -</em></p> <p>DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research http://www.streetinsider.com/Globe+Newswire/Humacyte+Announces+Presentation+at+VASA+Meeting+of+Research+Highlighting+Self-Repair+of+ATEV+After+Cannulation+for+Dialysis+Access/26546199.html Tue, 26 May 2026 08:00:00 -0400 A.31066700 A.50216777 HUMA O.22422661 O.39398241 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+19++Filed+by%3A+Sebelius+Kathleen/26528956.html si-local-file:///var/storage/secattach/20260520/26528956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+19++Filed+by%3A+Sebelius+Kathleen/26528956.html Wed, 20 May 2026 16:33:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+19++Filed+by%3A+Sebelius+Kathleen/26528956.html si-local-file:///var/storage/secattach/20260520/26528956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+19++Filed+by%3A+Sebelius+Kathleen/26528956.html Wed, 20 May 2026 16:33:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Constantino+Michael+T./26528939.html si-local-file:///var/storage/secattach/20260520/26528939.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Constantino+Michael+T./26528939.html Wed, 20 May 2026 16:32:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Constantino+Michael+T./26528939.html si-local-file:///var/storage/secattach/20260520/26528939.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Constantino+Michael+T./26528939.html Wed, 20 May 2026 16:32:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Parikh+Shamik+J/26528887.html si-local-file:///var/storage/secattach/20260520/26528887.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Parikh+Shamik+J/26528887.html Wed, 20 May 2026 16:31:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Parikh+Shamik+J/26528887.html si-local-file:///var/storage/secattach/20260520/26528887.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Parikh+Shamik+J/26528887.html Wed, 20 May 2026 16:31:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Sander+Dale+A./26528914.html si-local-file:///var/storage/secattach/20260520/26528914.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Sander+Dale+A./26528914.html Wed, 20 May 2026 16:31:00 -0400 HUMA O.39398241 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Sander+Dale+A./26528914.html si-local-file:///var/storage/secattach/20260520/26528914.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Humacyte%2C+Inc.++++++++++++For%3A+May+18++Filed+by%3A+Sander+Dale+A./26528914.html Wed, 20 May 2026 16:31:00 -0400 HUMA O.39398241 http://www.streetinsider.com/Corporate+News/HUMACYTE%27s+Symvess+receives+VA+contract+for+170+hospitals/26525184.html <p>Humacyte Inc. (NASDAQ: HUMA) announced that its Symvess product is now under contract with the Strategic Acquisition Center of the U.S. Department of Veterans Affairs. The contract provides access to 170 VA hospitals through the SAC SING (Surgical Implant – Next Generation) system.</p><p>The SAC serves as the primary sourcing vehicle for VA hospitals and requires intensive product and value analysis vetting by a surgical committee. The contract streamlines the approval process for individual hospitals within the VA system.</p><p>"We are pleased that Symvess is now under contract with the Strategic Acquisition Center, making the first-in-class product accessible to healthcare professionals treating http://www.streetinsider.com/Corporate+News/HUMACYTE%27s+Symvess+receives+VA+contract+for+170+hospitals/26525184.html Wed, 20 May 2026 08:03:11 -0400 HUMA